A Comparison of the Theory of Unpleasant Symptoms and the Conceptual Model of Chemotherapy-Related Changes in Cognitive Function

被引：27
作者：
Myers, Jamie S. [1 ]
机构：
[1] Univ Kansas, Med Ctr, Sch Nursing, Kansas City, KS 66103 USA
来源：
ONCOLOGY NURSING FORUM | 2009年 / 36卷 / 01期
关键词：
D O I：
10.1188/09.ONF.E1-E10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose/Objectives: To explore the use of the Theory of Unpleasant Symptoms (TUS) as a model for describing the symptom experience related to the cognitive impairment associated with standard-dose chemotherapy and compare and contrast that use of the TUS with the Conceptual Model of Chemotherapy-Related Changes in Cognitive Function. Data Sources: PubMed database. Data Synthesis: Retrospective and prospective clinical trials have substantiated the incidence of mild to moderate cognitive impairment. Patients have reported a significant effect on quality of life. Associated factors may include age, anemia, fatigue, depression, anxiety, hormone levels, cytokine release, and genetic makeup. Establishing the appropriateness of a working model to describe the relationships would provide additional structure and focus for empirical research. Conclusions: Both models have utility for describing the relationships of factors associated with chemotherapy-related cognitive impairment. Implications for Nursing: Blending of the TUS and the Conceptual Model of Chemotherapy-Related Changes in Cognitive Function may provide an enhanced framework for further research about the physiologic and psychological aspects of chemotherapy-related cognitive impairment.
引用
收藏
页码：33 / 33
页数：1
相关论文
共 45 条
  • [1] Ahles T.A., Saykin A., Cognitive effects of standard-dose chemotherapy in patients with cancer, Cancer Investigation, 19, 8, pp. 812-820, (2001)
  • [2] Ahles T.A., Saykin A.J., Breast cancer chemotherapy-related cognitive dysfunction, Clinical Breast Cancer, 3, SUPPL. 3, (2002)
  • [3] Ahles T.A., Saykin A.J., Candidate mechanisms for chemotherapy-induced cognitive changes, Nature Reviews. Cancer, 7, 3, pp. 192-201, (2007)
  • [4] Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., Et al., Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma, Journal of Clinical Oncology, 20, 2, pp. 485-493, (2002)
  • [5] Barnes D.E., Cauley J.A., Lui L.Y., Fink H.A., McCulloch C., Stone K.L., Et al., Women who maintain optimal cognitive function into old age, Journal of the American Geriatrics Society, 55, 2, pp. 259-264, (2007)
  • [6] Barsevick A.M., The elusive concept of the symptom cluster, Oncology Nursing Forum, 34, 5, pp. 971-980, (2007)
  • [7] Brady C.B., Spiro III A., Gaziano J.M., Effects of age and hypertension status on cognition: The Veterans Affairs Normative Aging Study, Neuropsychology, 19, 6, pp. 770-777, (2005)
  • [8] Chemotherapy and biotherapy guidelines and recommendations for practice, (2001)
  • [9] Chen M.L., Tseng H.H., Identification and verification of symptom clusters in cancer patients, Journal of Supportive Oncology, 3, 6 and SUPPL. 4, pp. 28-29, (2005)
  • [10] Chen Y., Jungsuwadee P., Vore M., Butterfield D.A., St. Clair D.K., Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues, Molecular Interventions, 7, 3, pp. 147-156, (2007)
12345